[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.48.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Special Communication
March 3, 1999

The Role of Meta-analysis in the Regulatory Process for Foods, Drugs, and Devices

Author Affiliations

Author Affiliations: Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia (Dr Berlin), and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School and Technology Assessment Group, Harvard School of Public Health, Boston, Mass (Dr Colditz).

JAMA. 1999;281(9):830-834. doi:10.1001/jama.281.9.830
Abstract

Synthesis of research findings has a long-standing tradition in science. While synthesis is currently required in the US food and drug regulatory process, formal meta-analysis may substitute for a pivotal study or broaden the generalizability of drug efficacy through a preplanned meta-analysis. Preplanned meta-analysis of individual trials with deliberately introduced heterogeneity may maximize the generalizability of results from randomized trials. Combining observational data may help to support an alternative claim or to quantify adverse events. In this setting, methods to address potentially greater sources of bias are required. Overall, meta-analysis adds evidence through the synthesis study findings and permits examination of how treatment effects vary across of subgroups, such as age and sex, and across study settings.

×